This shortened version can be used not only in preclinical AD, but also in prodromal AD, making it possible to discriminate between normal aging and MCI, with the latter group converting to dementia in most cases. In contrast with the original FNAME, the FNAME-12 comprises fewer stimuli, an additional learning trial, and a delayed memory recognition task. Ī shortened and optimized version of the FNAME (FNAME-12), whose scores are strongly correlated with those on the original FNAME ( r = 0.77), was recently created and subsequently validated in American, Latino American, and Greek populations. Moreover, low scores on the original and Spanish (S-FNAME) versions of the FNAME have been found to be associated with biomarker evidence of increased cerebral amyloid burden, quantified by positron emission tomography in healthy elderly. Patients with mild cognitive impairment (MCI) have lower performances on the FNAME than cognitively healthy (CH) individuals. The FNAME is an associative episodic memory test that has been validated in American and Spanish populations. The Face-Name Associative Memory Exam (FNAME) was developed to detect preclinical AD. It implicates associative occipito-temporal cerebral regions with extensive connections to cortical areas, which is the specific neural function disrupted in AD. Cognitive approaches conceptualizing face-name associative memory have demonstrated that associating unfamiliar faces with proper names is a task more complex than other visual memory tests because this is an arbitrary association. One of the endophenotypes proposed for Alzheimer’s disease (AD) is episodic memory tests. Our findings suggest FACEmemory® performance provides a useful gradation of impairment from normal aging to aMCI, and it is related to CSF AD biomarkers. ConclusionsįACEmemory® may be a promising memory prescreening tool for detecting subtle memory deficits related to AD. FACEmemory® scores and AD CSF biomarker levels were significantly correlated as well, mainly in the aMCI group. Automatically corrected FACEmemory® scores were highly correlated with the manually corrected ones. A cutoff of 31.5 in total FACEmemory® obtained 80.5% and 80.3% sensitivity and specificity values, respectively, for discriminating between CH and aMCI. Performance on FACEmemory® was progressively worse from CH to the naMCI and aMCI groups. A subsample of 65 individuals completed the S-FNAME, and 65 subjects received lumbar punctures. MethodsįACEmemory® was completed by 154 cognitively healthy (CH) individuals and 122 subjects with mild cognitive impairment, of whom 61 were non-amnestic (naMCI) and 61 amnestic (aMCI). The aims of the present study were (1) to determine whether FACEmemory® is a sensitive tool for the detection of cognitive impairment, (2) to examine whether performances on FACEmemory® are correlated with those on the S-FNAME (paper-and-pencil version with 16 images), and (3) to determine whether performances on FACEmemory® are related to AD biomarkers in the cerebrospinal fluid (CSF) (Aβ42, p-tau, and Aβ42/p-tau ratio). The test was minimally supervised by a psychologist to avoid technological problems during execution and scored manually to assess the reliability of the automatic scoring. The purpose of this study is to create the first self-administered episodic memory test, FACEmemory®, by adapting the FNAME-12 for tablet use with voice recognition, touchscreen answers, and automatic scoring. The current work advances this field by using voice recognition and touchscreen response format. The short form of the Face-Name Associative Memory Exam (FNAME-12), developed to detect preclinical and prodromal AD, asks individuals to learn the names and occupations associated with 12 faces. It implicates associative occipito-temporal cerebral regions, which are disrupted in AD. Memory for faces and proper names is a complex task because its association is arbitrary. Computerized neuropsychological tests for early detection of Alzheimer’s disease (AD) have attracted increasing interest.
0 Comments
Leave a Reply. |